Spritam is a drug owned by Aprecia Pharmaceuticals Llc. It is protected by 5 US drug patents filed from 2015 to 2021. Out of these, 3 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 14, 2034. Details of Spritam's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11160786 | Rapid disperse dosage form |
Mar, 2034
(9 years from now) | Active |
| US9339489 | Rapid disperse dosage form containing levetiracetam |
Mar, 2034
(9 years from now) | Active |
| US9669009 | Rapid disperse dosage form containing levetiracetam |
Mar, 2034
(9 years from now) | Active |
| US6471992 | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
Feb, 2018
(6 years ago) |
Expired
|
| US9463160 | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
Feb, 2018
(6 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Spritam's patents.
Latest Legal Activities on Spritam's Patents
Given below is the list of recent legal activities going on the following patents of Spritam.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Post Issue Communication - Certificate of Correction | 26 Jan, 2022 | US11160786 |
| Patent Issue Date Used in PTA Calculation Critical | 02 Nov, 2021 | US11160786 |
| Recordation of Patent Grant Mailed Critical | 02 Nov, 2021 | US11160786 |
| Email Notification Critical | 14 Oct, 2021 | US11160786 |
| Issue Notification Mailed Critical | 13 Oct, 2021 | US11160786 |
| Application Is Considered Ready for Issue Critical | 01 Oct, 2021 | US11160786 |
| Dispatch to FDC | 01 Oct, 2021 | US11160786 |
| Issue Fee Payment Verified Critical | 28 Sep, 2021 | US11160786 |
| Issue Fee Payment Received Critical | 28 Sep, 2021 | US11160786 |
| Email Notification Critical | 01 Sep, 2021 | US11160786 |
US patents provide insights into the exclusivity only within the United States, but Spritam is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Spritam's family patents as well as insights into ongoing legal events on those patents.
Spritam's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Spritam's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 14, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Spritam Generic API suppliers:
Levetiracetam is the generic name for the brand Spritam. 75 different companies have already filed for the generic of Spritam, with Prinston Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Spritam's generic
Alternative Brands for Spritam
Spritam which is used for treating seizures or epilepsy., has several other brand drugs using the same active ingredient (Levetiracetam). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Tripoint |
| ||
| Ucb Inc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Levetiracetam, Spritam's active ingredient. Check the complete list of approved generic manufacturers for Spritam
About Spritam
Spritam is a drug owned by Aprecia Pharmaceuticals Llc. It is used for treating seizures or epilepsy. Spritam uses Levetiracetam as an active ingredient. Spritam was launched by Aprecia Pharms in 2015.
Approval Date:
Spritam was approved by FDA for market use on 31 July, 2015.
Active Ingredient:
Spritam uses Levetiracetam as the active ingredient. Check out other Drugs and Companies using Levetiracetam ingredient
Treatment:
Spritam is used for treating seizures or epilepsy.
Dosage:
Spritam is available in tablet, for suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 750MG | TABLET, FOR SUSPENSION | Prescription | ORAL |
| 500MG | TABLET, FOR SUSPENSION | Prescription | ORAL |
| 250MG | TABLET, FOR SUSPENSION | Prescription | ORAL |
| 1GM | TABLET, FOR SUSPENSION | Prescription | ORAL |